As of 2024-07-27, the EV/EBITDA ratio of Enanta Pharmaceuticals Inc (ENTA) is -2.01. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ENTA's latest enterprise value is 266.59 mil USD. ENTA's TTM EBITDA according to its financial statements is -132.83 mil USD. Dividing these 2 quantities gives us the above ENTA EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 16.0x | 12.4x |
| Forward P/E multiples | 15.7x - 21.3x | 18.2x |
| Fair Price | (95.53) - (97.16) | (93.02) |
| Upside | -715.5% - -726.0% | -699.4% |
| Date | EV/EBITDA |
| 2024-07-26 | -2.01 |
| 2024-07-25 | -1.98 |
| 2024-07-24 | -1.93 |
| 2024-07-23 | -1.92 |
| 2024-07-22 | -1.87 |
| 2024-07-19 | -1.82 |
| 2024-07-18 | -1.88 |
| 2024-07-17 | -2.05 |
| 2024-07-16 | -2.11 |
| 2024-07-15 | -2.17 |
| 2024-07-12 | -2.08 |
| 2024-07-11 | -1.92 |
| 2024-07-10 | -1.86 |
| 2024-07-09 | -1.83 |
| 2024-07-08 | -1.71 |
| 2024-07-05 | -1.67 |
| 2024-07-03 | -1.63 |
| 2024-07-02 | -1.68 |
| 2024-07-01 | -1.62 |
| 2024-06-28 | -1.60 |
| 2024-06-27 | -1.55 |
| 2024-06-26 | -1.48 |
| 2024-06-25 | -1.49 |
| 2024-06-24 | -1.48 |
| 2024-06-21 | -1.43 |
| 2024-06-20 | -1.35 |
| 2024-06-18 | -1.42 |
| 2024-06-17 | -1.46 |
| 2024-06-14 | -1.58 |
| 2024-06-13 | -1.67 |
| 2024-06-12 | -1.65 |
| 2024-06-11 | -1.67 |
| 2024-06-10 | -1.57 |
| 2024-06-07 | -1.59 |
| 2024-06-06 | -1.53 |
| 2024-06-05 | -1.51 |
| 2024-06-04 | -1.48 |
| 2024-06-03 | -1.51 |
| 2024-05-31 | -1.52 |
| 2024-05-30 | -1.45 |
| 2024-05-29 | -1.43 |
| 2024-05-28 | -1.43 |
| 2024-05-24 | -1.45 |
| 2024-05-23 | -1.46 |
| 2024-05-22 | -1.57 |
| 2024-05-21 | -1.52 |
| 2024-05-20 | -1.52 |
| 2024-05-17 | -1.47 |
| 2024-05-16 | -1.61 |
| 2024-05-15 | -1.66 |